BPC-157 + TB-500 Blend vs Klow

What this comparison covers

Both products are multi-peptide research blends supplied as lyophilized powder in a single sealed vial. The BPC-157 + TB-500 Blend combines two peptides in equal parts; Klow is a trade name for a four-peptide mixture of GHK-Cu, BPC-157, TB-500 and KPV. This page sets the two side by side on composition, fill amount, verified identifiers and the state of the published evidence for each component.

It does not rank them. Neither blend has its own body of peer-reviewed research, and this page makes no statement about use, administration or outcomes. Every scientific claim below is drawn from the sources cited on the two product pages and listed at the end.

Shared ground

Two ingredients are common to both vials: BPC-157, a 15-amino-acid peptide described as a stable fragment of a gastric protein, and TB-500, the N-terminal acetylated 17–23 fragment of thymosin β4 ^[4]. Almost everything published about these two comes from animal tissue-repair models; a 2025 systematic review of BPC-157 found 35 preclinical studies and a single human case series, all low-level evidence ^[1].

Both blends therefore inherit the same caveats. No study has examined either fixed mixture. The one experiment that tested BPC-157 and TB-500 together, a 2026 rat Achilles-tendon study, reported no added benefit from combining them over either peptide alone ^[5]. FDA has noted that it has no human exposure data for the TB-500 fragment and only limited safety information for BPC-157 ^[6], and both substances appear on the WADA 2026 Prohibited List.

Both are sold by Renuvia Labs for laboratory research use only, with the same documentation: verified identifiers on the product page and a lot Certificate of Analysis published in the COA library once testing is complete.

How they differ

Composition is the main difference. The BPC-157 + TB-500 Blend contains those two peptides in a 1:1 ratio and nothing else. Klow adds GHK-Cu, a copper-bound tripeptide (glycyl-histidyl-lysine) that occurs naturally in human plasma ^[2], and KPV, the tripeptide Lys-Pro-Val that forms residues 11–13 of α-melanocyte-stimulating hormone ^[3].

Fill amount differs accordingly: the two-peptide blend is a 10 mg vial, Klow is an 80 mg vial. The table above lists the fill amounts and the identifiers verified for each product; because both are mixtures, neither has a single sequence, formula or CAS number of its own.

The evidence base is broader for Klow's extra components but belongs to different research traditions. GHK-Cu has a long record in skin and wound research, including small human studies of topical cosmetic products and gene-expression profiling ^[2]. KPV has been studied in intestinal cell lines and mouse colitis models, where it is carried into cells by the peptide transporter PepT1 ^[3]. Neither has been studied in combination with BPC-157 or TB-500.

Which research questions each is associated with

The BPC-157 + TB-500 Blend is associated in the literature with musculoskeletal repair questions: tendon, ligament, muscle and bone injury models in rodents for BPC-157 ^[1], and cell migration and new blood-vessel formation for the parent protein thymosin β4, whose short TB-500 fragment is less well characterized ^[4][5].

Klow is associated with those same questions plus two more: skin and collagen biology, where GHK-Cu is proposed to shift the expression of repair-related genes and stimulate collagen and elastin production in cell and animal models ^[2], and intestinal inflammation, where KPV dampens NF-κB and MAP-kinase signaling in cell and mouse experiments ^[3].

In both cases the research belongs to the individual ingredients, mostly at the cell and animal level. Researchers choosing between the vials are choosing which set of component peptides, and which set of unanswered questions, they want to work with.

Questions researchers ask

Does Klow contain the same BPC-157 and TB-500 as the two-peptide blend?

Both vials contain BPC-157 and the acetylated 17–23 thymosin β4 fragment sold as TB-500 ^[4]. Klow adds GHK-Cu and KPV. Each product page lists the verified identifiers for its components and the lot Certificate of Analysis once it is published.

Why is there no sequence, molecular weight or CAS number for either blend?

Those identifiers describe a single compound. Both products are mixtures, so the product pages list identifiers per component where they have been verified, and the blend itself has none.

Has either blend been studied as a combination?

No peer-reviewed study of either fixed mixture was identified. One 2026 rat tendon study tested BPC-157 and TB-500 alone and together and found no added benefit from the combination ^[5]. The four-way Klow mixture has not been studied.

Which has more published research behind it?

Klow's extra components, GHK-Cu and KPV, each have their own literature, so more papers touch its ingredients. That is not evidence for the blend: all four ingredients are studied separately, mostly in cell and animal models, and none is an approved drug.

Are these products for human use?

No. Both are sold for laboratory research use only by qualified researchers. They are not drugs, dietary supplements, cosmetics or foods and have not been evaluated by the FDA for any use.

Sources

1. Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J 2025
2. Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci 2018
3. Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology 2008
4. Esposito S, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500. Drug Test Anal 2012
5. Biçer M, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats. Jt Dis Relat Surg 2026
6. FDA. Certain bulk drug substances for use in compounding that may present significant safety risks (updated Apr 2026)